P/E at 24.09 vs Industry's 35.74: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The P/E ratio of 24.09 for Dr Reddys Laboratories Ltd stands in stark contrast to the industry average of 35.74, signalling a valuation discount of approximately 33%. This lower multiple suggests that the market is pricing in either slower growth prospects or elevated risks relative to peers. In the context of the Pharmaceuticals & Biotechnology sector, where many companies command premium valuations due to innovation pipelines and regulatory approvals, such a discount is notable. It raises the question of whether the market is factoring in recent operational challenges or broader sector headwinds — what is the current rating for Dr Reddys Laboratories Ltd given this valuation gap?

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns across multiple timeframes reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 3.38%, modestly outperforming the Sensex’s 5.10% fall. However, the shorter-term figures paint a less favourable picture. The stock has lost 1.54% over the past week and 4.40% over the last month, while the Sensex gained 1.02% in the same month. The three-month performance shows a decline of 1.36%, slightly worse than the Sensex’s 1.19% fall. Year-to-date, the stock is down 4.37%, outperforming the Sensex’s 8.96% drop. This divergence between short-term weakness and relative resilience over longer periods — is this a temporary setback or indicative of deeper structural issues? — is a key consideration for investors.

Moving Average Configuration: Bearish Technical Setup

The technical indicators for Dr Reddys Laboratories Ltd suggest a bearish trend. The stock is trading below all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained downward momentum. This configuration typically signals that the stock is in a prolonged downtrend, with short-term rallies likely to face resistance. Notably, the stock has just ended a three-day losing streak with a 0.39% gain today, outperforming the sector by 0.8%. However, the intraday volatility remains high at 61.01%, reflecting uncertainty and potential price swings. The current technical setup raises the question — is this a genuine recovery or a relief rally that will fade at the resistance levels?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently, with a combination of positive, flat, and negative performances across constituent stocks. Dr Reddys Laboratories Ltd’s relative outperformance over the one-year and year-to-date periods suggests some resilience amid sector volatility. However, the sector’s average P/E of 35.74 reflects investor optimism about growth and innovation, contrasting with the stock’s more conservative valuation. This divergence may be influenced by company-specific factors such as pipeline developments, regulatory challenges, or earnings trends — how does this valuation-performance gap affect the stock’s outlook?

Rating Reassessment: Previously Hold, Now Updated

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold, reflecting a reassessment of its fundamentals and market position. The Mojo Score currently stands at 41.0, with a large-cap market capitalisation of ₹1,01,459.02 crores. This rating change coincides with the stock’s valuation discount and mixed performance metrics, suggesting a more cautious stance. The question remains — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Long-Term Performance: Lagging Behind Benchmarks

Over extended periods, Dr Reddys Laboratories Ltd has underperformed the Sensex. The three-year return is 13.80% compared to the Sensex’s 14.82%, while the five-year return is 13.81% against the Sensex’s 48.64%. The ten-year return of 65.19% also trails the Sensex’s 177.93%. These figures highlight that despite being a large-cap stalwart in the Pharmaceuticals & Biotechnology sector, the stock has not kept pace with broader market gains over the long term. This underperformance may contribute to the valuation discount and cautious rating stance.

Summary: What the Data Collectively Shows

The data for Dr Reddys Laboratories Ltd reveals a stock trading at a significant valuation discount to its sector, with a P/E of 24.09 versus the industry’s 35.74. While the one-year and year-to-date returns modestly outperform the Sensex, shorter-term performance and technical indicators point to ongoing challenges. The stock’s position below all major moving averages and high intraday volatility underscore a cautious technical outlook. Long-term returns lag behind broader market benchmarks, reinforcing the tempered valuation. Previously rated Hold, the company’s rating was updated recently, reflecting these mixed signals — should investors reassess their stance on Dr Reddys Laboratories Ltd in light of this data?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →